Table 1 Association between average methylation and breast cancer risk in EPIC and NOWAC
|
Cases (n) |
Controls (n) | OR | (95 % CI) | p value | ||
|---|---|---|---|---|---|---|
| EPIC | ||||||
| By quartile | Q1 [0.529–0.546] | 75 | 41 | 1.00 | ||
| Q2 [0.546–0.549] | 31 | 40 | 0.46 | (0.25–0.84) | 0.01 | |
| Q3 [0.549–0.551] | 30 | 40 | 0.40 | (0.21–0.76) | 0.005 | |
| Q4 [0.551–0.560] | 26 | 41 | 0.34 | (0.18–0.66) | 0.001 | |
| Per 1 SD | 162 | 162 | 0.61 | (0.46–0.80) | 0.0003 | |
| Time to diagnosis | <3.8 | 81 | 81 | 0.66 | (0.46–0.94) | 0.02 |
| (years) | >3.8 | 81 | 81 | 0.54 | (0.35–0.83) | 0.005 |
| p het = 0.483 | ||||||
| ER status | Negative | 18 | 18 | 0.49 | (0.20–1.24) | 0.13 |
| Positive | 56 | 56 | 0.59 | (0.36–0.96) | 0.03 | |
| p het = 0.725 | ||||||
| NOWAC | ||||||
| By quartile | Q1 [0.527–0.538] | 45 | 42 | 1.00 | ||
| Q2 [0.538–0.540] | 32 | 42 | 0.74 | (0.41–1.34) | 0.32 | |
| Q3 [0.540–0.543] | 46 | 42 | 1.04 | (0.59–1.85) | 0.88 | |
| Q4 [0.543–0.551] | 45 | 42 | 0.99 | (0.56–1.76) | 0.98 | |
| Per 1 SD | 168 | 168 | 1.03 | (0.82–1.30) | 0.81 | |
| Time to diagnosis | <2.1 | 84 | 84 | 0.92 | (0.66–1.29) | 0.62 |
| (years) | >2.1 | 84 | 84 | 1.15 | (0.83–1.60) | 0.41 |
| p het = 0.351 | ||||||
| ER status | Negative | 28 | 28 | 0.80 | (0.48–1.32) | 0.38 |
| Positive | 130 | 130 | 1.10 | (0.84–1.44) | 0.50 | |
| p het = 0.276 | ||||||
